Umbilical cord blood transplantation: the first 25 years and beyond

Blood

Volumn 122, Issue 4, 2013, Pages 491-498

  Ballen, Karen K ^a   Gluckman, Eliane ^b   Broxmeyer, Hal E ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; NICOTINAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; DEGENERATIVE DISEASE; DISEASE FREE SURVIVAL; EX VIVO STUDY; FANCONI ANEMIA; FOLLOW UP; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; LOW DRUG DOSE; LYMPH NODE IRRADIATION; MESENCHYMAL STEM CELL; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL RATE; WHOLE BODY RADIATION; ADULT; CHILD; CYTOLOGY; FETUS BLOOD; HISTORY; METHODOLOGY; NEWBORN; PHYSIOLOGY;

ADULT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HEMATOLOGIC DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT, NEWBORN;

EID: 84885934963     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-453175     Document Type: Review

References (96)

1. Appelbaum FR. Pursuing the goal of a donor for everyone in need. N Engl J Med. 2012; 367(16): 1555-1556.
2. Barker JN, Byam CE, Kernan N.A., et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 2010; 16(11): 1541-1548.
3. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA. 1989; 86(10): 3828-3832. (Pubitemid 19141838)
4. Gluckman E, Broxmeyer HA, Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989; 321(17): 1174-1178. (Pubitemid 19255814)
5. Wagner JE, Broxmeyer HE, Byrd R.L., et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992; 79(7): 1874-1881.
6. Kohli-Kumar M., Shahidi NT, Broxmeyer H.E., et al. Haemopoietic stem/progenitor cell transplant in Fanconi anaemia using HLA-matched sibling umbilical cord blood cells. Br J Haematol. 1993; 85(2): 419-422. (Pubitemid 23309586)
7. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer H.E., Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995; 346(8969): 214-219.
8. Broxmeyer HE, Kurtzberg J, Gluckman E., et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells. 1991; 17(2): 313-329.
9. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011; 117(18): 4773-4777.
10. Vormoor J, Lapidot T, Pflumio F., Risdon G, Patterson B, Broxmeyer H.E., Dick JE. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood. 1994; 83(9): 2489-2497. (Pubitemid 24135840)
11. Bock TA, Orlic D, Dunbar C.E., Broxmeyer HE, Bodine DM. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med. 1995; 182(6): 2037-2043.
12. Broxmeyer HE, Gluckman E, Auerbach A., et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning. 1990; 8(Suppl 1): 76-89, discussion 89-91
13. Carow CE, Hangoc G, Cooper S.H., Williams DE, Broxmeyer HE. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential. Blood. 1991; 78(9): 2216-2221.
14. Lu L, Xiao M, Shen R.N., Grigsby S., Broxmeyer HE. Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood. 1993; 81(1): 41-48. (Pubitemid 23013675)
15. Carow CE, Hangoc G, Broxmeyer HE. Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. Blood. 1993; 81(4): 942-949. (Pubitemid 23054830)
16. Broxmeyer HE, Hangoc G, Cooper S., et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA. 1992; 89(9): 4109-4113.
17. Auerbach AD, Liu Q, Ghosh R., Pollack MS, Douglas GW, Broxmeyer HE. Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion. 1990; 30(8): 682-687. (Pubitemid 20361781)
18. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1983; 54(3): 431-440. (Pubitemid 13054564)
19. Gluckman E, Auerbach AD, Horowitz M.M., et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995; 86(7): 2856-2862.
20. Rubinstein P, Carrier C, Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998; 339(22): 1565-1577. (Pubitemid 28536131)
21. Gluckman E, Ruggeri A, Rocha V., et al. Family-directed umbilical cord blood banking. Haematologica. 2011.96:(11): 1701-1707.
22. Gluckman E, Rocha V, Boyer-Chammard A, et al.; Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997; 337(6): 373-381. (Pubitemid 27328367)
23. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz M.M., Gluckman E; Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med. 2000; 342(25): 1846-1854. (Pubitemid 30419048)
24. Herr AL, Kabbara N, Bonfim C.M., et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood. 2010; 116(11): 1849-1856.
25. Kurtzberg J, Laughlin M, Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996; 335(3): 157-166. (Pubitemid 26249452)
26. Wagner JE, Barker JN, DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002; 100(5): 1611-1618. (Pubitemid 34925136)
27. Gluckman E, Rocha V, Arcese W., et al.; Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004; 32(4): 397-407. (Pubitemid 38410917)
28. Locatelli F, Rocha V, Chastang C., et al.; EurocordCord Blood Transplant Group. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood. 1999; 93(11): 3662-3671. (Pubitemid 29249812)
29. Bizzetto R, Bonfim C, Rocha V., et al.; Eurocord and SAA-WP from EBMT. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. 2011; 96(1): 134-141.
30. Wagner JE, Rosenthal J, Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996; 88(3): 795-802. (Pubitemid 26333297)
31. Rocha V, Cornish J, Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001; 97(10): 2962-2971.
32. Fernandes JF, Rocha V, Labopin M., et al.; Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012; 119(12): 2949-2955.
33. Eapen M, Rubinstein P, Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007; 369(9577): 1947-1954. (Pubitemid 46874578)
34. Hwang WY, Samuel M, Tan D., Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2007; 13(4): 444-453. (Pubitemid 46421885)
35. Ruggeri A, Eapen M, Scaravadou A., et al.; Eurocord Registry; Center for International Blood and Marrow Transplant Research; New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011; 17(9): 1375-1382.
36. Gluckman E, Rocha V, Ionescu I., et al.; Eurocord Netcord and EBMT. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant. 2007; 13(9): 1073-1082. (Pubitemid 47215564)
37. Wagner JE, Eapen M, Carter S.L., et al. No survival advantage after double vs single cord blood transplantation in children with hematologic malignancy. Blood. 2012; 120(21): 359a. [abstract]
38. Ballen KK, Klein JP, Pedersen T.L., et al. Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012; 18(6): 903-912.
39. Laughlin MJ, Barker J, Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001; 344(24): 1815-1822. (Pubitemid 32538694)
40. Cohen YC, Scaradavou A, Stevens C.E., et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 2011; 46(1): 70-76.
41. Robin M, Sanz GF, Ionescu I, et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia. 2011; 25(1): 75-81.
42. Sanz J, Boluda JC, Martín C, et al.; Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH). Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant. 2012; 47(10): 1287-1293.
43. Ooi J, Takahashi S, Tomonari A., et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2008; 14(12): 1341-1347.
44. Giralt S, Ballen K, Rizzo D., et al. Reduced-intensity conditioning regiment workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Bone Marrow Transplant Research. Biol Blood Marrow Transplant. 2009; 15(3): 367-369.
45. Bacigalupo A, Ballen KK, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12): 1628-1633.
46. Barker JN, Weisdorf DJ, DeFor T.E., Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003; 102(5): 1915-1919. (Pubitemid 37022593)
47. Ballen KK, Spitzer TR, Yeap B.Y., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007; 13(1): 82-89. (Pubitemid 46044092)
48. Rocha V, Mohty M, Gluckman E., Rio B; Eurocord; Reduced-Intensity Conditioning Subcommittee of the Acute Leukaemia Working Party; French Society of Bone Marrow Transplantation and Cellular Therapy. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Curr Opin Oncol. 2009; 21(SUPPL. 1):S31-S34.
49. Cutler C, Stevenson K, Kim H.T., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011; 46(5): 659-667.
50. Rocha V, Labopin M, Ruggeri A., et al. Outcomes after Double Cord Blood Transplant compared to single cord blood transplant in adults with hematologic malignancy [abstract]. Blood. 2012; 120(21): 242a.
51. Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013; 121(5): 752-758.
52. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011; 117(8): 2332-2339.
53. Gluckman E, Ruggeri A, Volt F., Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. Br J Haematol. 2011; 154(4): 441-447.
54. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010; 115(9): 1843-1849.
55. Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011; 118(25): 6691-6697.
56. Ruggeri A, Rocha V, Masson E., et al. Impact of donor specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation. A Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis [published online ahead of print December 14, 2012]. Haematologica. 2012.
57. Takanashi M, Atsuta Y, Fujiwara K., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010; 116(15): 2839-2846.
58. Rocha V, Spellman S, Zhang M.J., et al.; Eurocord-European Blood and Marrow Transplant Group and the Center for International Blood and Marrow Transplant Research. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012; 18(12): 1890-1896.
59. van Rood J.J., Stevens CE, Smits J, Carrier C., Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci USA. 2009; 106(47): 19952-19957.
60. Eapen M, Klein JP, Sanz G.F., et al.; Eurocord-European Group for Blood and Marrow Transplantation; Netcord; Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011; 12(13): 1214-1221.
61. Garfall A, Kim H, Cutler C., et al. Allele level matching at HLA-C or DRB1 is associated with improved survival after reduced intensity cord blood transplantation. Blood. 2012; 120(21): 2010a. [abstract]
62. Willemze R, Rodrigues CA, Labopin M, et al.; Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009; 23(3): 492-500.
63. Brunstein CG, Wagner JE, Weisdorf D.J., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009; 113(22): 5628-5634.
64. Ballen KK, Koreth J, Chen Y.B., Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012; 119(9): 1972-1980.
65. Eapen M, Rocha V, Sanz G., et al.; Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010; 11(7): 653-660.
66. Brunstein CG, Gutman JA, Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010; 116(22): 4693-4699.
67. Ponce DM, Zheng J, Gonzales A.M., et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(9): 1316-1326.
68. Chen YB, Aldridge J, Kim H.T., et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012; 18(5): 805-812.
69. Brunstein CG, Eapen M, Ahn K.W., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012; 119(23): 5591-5598.
70. Brunstein CG, Fuchs EJ, Carter S.L., et al.; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118(2): 282-288.
71. Broxmeyer HE, Cooper S, Hass D.M., Hathaway JK, Stehman FB, Hangoc G. Experimental basis of cord blood transplantation. Bone Marrow Transplant. 2009; 44(10): 627-633.
72. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011; 118(24): 6438-6445.
73. Bautista G, Cabrera JR, Regidor C, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant. 2009; 43(5): 365-373.
74. Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008; 9(9): 831-839.
75. Brunstein CG, Barker JN, Weisdorf D.J., et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009; 43(12): 935-940.
76. Rocha V, Labopin M, Ruggeri A., et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematologic malignancies [published online ahead of print March 15, 2013]. Transplantation. 2013.
77. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H., Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010; 16(2): 232-236.
78. de Lima M., McNiece I, Robinson S.N., et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012; 367(24): 2305-2315.
79. Horowitz ME, Stiff PJ, Chao N.J., et al. Nicord expanded hematpoietic progenitor cells (HPC) are capable of outcompeting the unmanipulated cord blood unit and of prolonged myeloid and lymphoid engraftment following myeloablative dual umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2013; 19:S119-S128. [abstract]
80. Boitano AE, Wang J, Romeo R., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010; 329(5997): 1345-1348.
81. Rohrabaugh SL, Campbell TB, Hangoc G, Broxmeyer HE. Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice. Blood Cells Mol Dis. 2011; 46(4): 318-320.
82. Robinson SN, Simmons PJ, Thomas M.W., et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rg(null) mice. Exp Hematol. 2012; 40(6): 445-456.
83. Christopherson KW I.I., Hangoc G, Mantel C.R., Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004; 305(5686): 1000-1003. (Pubitemid 39071774)
84. Campbell TB, Hangoc G, Liu Y., Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 2007; 16(3): 347-354.
85. Cutler CS, Shoemaker D, Ballen K.K., et al. FT 1050(16,16 dimethyl Prostaglandin E2)-enhanced umbilical cord blood accelerates hematopoietic engraftment after reduced intensity conditioning and double umbilical cord blood transplantation. Blood. 2011; 118: 653a. [abstract]
86. Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell. 2011; 8(4): 445-458.
87. Farag SS, Srivastava S, Messina-Graham S, et al. In-vivo inhibition to enhance engraftment of single-unit cord blood transplants in adults with high-risk hematological malignancies. Stem Cells Dev. 2013; 22(7): 1007-1015.
88. Broxmeyer HE, Hoggatt J, O'Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012; 18(12): 1786-1796.
89. Broxmeyer HE, ed. Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press; 2011.
90. Broxmeyer HE, Farag SS, Rocha V. Cord Blood Hematopoietic Cell Transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Antin JH, eds. Thomas' Hematopoietic Cell Transplantation. 5th ed. Oxford, England: Wiley Blackwell; 2013
91. Ballen KK, Cutler C, Yeap B.Y., et al. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010; 16(7): 1025-1031.
92. Sauter C, Abboud M, Jia X., et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant. 2011; 17(10): 1460-1471.
93. Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell. 2010; 6(1): 21-24.
94. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012; 481(7381): 295-305.
95. Takahashi S, Ooi J, Tomonari A., et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007; 109(3): 1322-1330. (Pubitemid 46220686)
96. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al.; Japan Cord Blood Bank Network. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009; 113(8): 1631-1638.